News & Events

Researchers at the Johns Hopkins University have tested an alternative route to deliver gene therapy vectors to the retina that could potentially help patients with age-related macular degeneration (AMD) and inherited retinal disorders (IRDs). The new route of administration, called suprachoroidal injection, has been investigated initially in preclinical experiments in animals and uses a microneedle to inject gene-carrying therapeutic viruses...

World Sight Day to raise awareness of blindness and visual impairment

09/10/19 - Patients,

World Sight Day is observed annually on the second Thursday of October. This global event coordinated by The International Agency for the Promotion of Blindness (IAPB) in cooperation with the World Health Organization (WHO) is meant to raise public awareness of blindness and vision impairment as major international public health issues. World Sight Day aims to influence governments/ministers of health...

Gene therapies open very promising scenarios for the treatment of genetic blindness

23/09/19 - Retinal Dystrophy, Gene Therapy,

Not so far ago, a patient that was clinically diagnosed with a retinal inherited dystrophy had to face an unavoidable outcome, eventual blindness. No effective treatment to cure or halt the progression of the disease was available. This gloomy perspective has been completely upturned by the implementation of cutting edge technologies, and the future looks promising for patients and their...

New RNA therapy for autosomal dominant retinitis pigmentosa

27/08/19 - Retinal Dystrophy, Gene Therapy,

The United States Food and Drug Administration (FDA) has just approved the designation of the QR-1123 therapy by the Dutch company ProQR as a new investigational drug. This drug aims to treat a form of autosomal dominant retinitis pigmentosa (RPad) caused by the P23H mutation in the rhodopsin gene (RHO). QR-1123 is an antisense oligonucleotide, that is, a short RNA...

A race against the clock for Leber congenital amaurosis gene therapy

14/08/19 - Leber Congenital Amaurosis, Retinal Dystrophy, Gene Therapy,

ProQR Sepofarsen therapy On July 29, the Dutch company ProQR announced that the European Medicines Agency (EMA) has granted access to the Agency's priority medicine program (PRIME) to its Sepofarsen therapy (QR-110), designed for the treatment of Leber congenital amaurosis (LCA10), a childhood blinding disorder, caused by the c.2991+1655A>G (p.Cys998 *) mutation in the CEP290 gene. The EMA PRIME program...

DBGen presents a research optimizing the genetic diagnosis of color vision deficiency

09/07/19 - DBGen, Genetic Diagnosis, Research,

DBGen is committed to the quality of genetic diagnosis and its major goal since the beginning of the company is to remain at the forefront of innovation, prioritize resolution of difficult cases, and optimize methodologies that increase the diagnostic yield of inherited ocular diseases. These objectives are clearly attainable due to the high expertise in the field of genetic diagnosis...

< 1 2 3 4 … 7 >